About the Journal
Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies. The journal also publishes News and Research Watch sections.Read More About the Journal
Samantha B. Kemp, et al.
Noted This Week
The FDA granted accelerated approval to tucatinib (Tukysa; Seagen) in combination with trastuzumab for certain cases of inoperable RAS wild-type, HER2-positive metastatic colorectal cancer based on results of a phase II trial. In 84 patients who had previously received chemotherapy and a VEGF mAb, the HER2 inhibitor duo yielded an overall response rate (ORR) of 38% and a duration of response (DOR) of 12.4 months. The most common side effects were diarrhea, nausea, vomiting, rash, and hepatotoxicity.